Article Text
Statistics from Altmetric.com
In the article Should rare diseases get special treatment? by Monica Q F de Magalhaes,1 it is argued that rarity is not a morally relevant feature to consider in prioritising treatment in healthcare, but severity is. A central conclusion in the article is that severity rather than prevalence should guide different cost-effectiveness thresholds. Hence, I take it, she answers no to the question in her own heading. I agree with all of this—and with most of her other arguments and conclusions in the article—except for the clause ‘rather than prevalence’. For this reason, I find the article misses its’ mark (even if not by much). Let me explain by taking Sweden as an example.
Sweden has a legally established ethics framework for priority setting in healthcare since 1997, comprising three principles: human-dignity principle, needs-solidarity principle and cost-effectiveness principle. The implication of these principles in practice is that the higher the severity—the higher the cost-effectiveness threshold acceptable.2 During the last 10 years or so, the highest accepted cost-effectiveness threshold for the most severe conditions have been in the order of €100 000/QALY. Until a few years ago rarity or prevalence was …
Footnotes
Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
Linked Articles
- Feature article
Read the full text or download the PDF:
Other content recommended for you
- Should rare diseases get special treatment?
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Does NICE apply the rule of rescue in its approach to highly specialised technologies?
- Effectiveness, safety and costs of orphan drugs: an evidence-based review
- Ethical issues in funding orphan drug research and development
- Rare diseases in healthcare priority setting: should rarity matter?
- Reforming EU and national orphan drug regulations to improve outcomes for patients with rare diseases
- Orphan drugs and the NHS: should we value rarity?